Clinical Trial: Phase III Clinical Trial of Recombinant Respiratory Syncytial Virus Vaccine (CHO Cells)

U.S., Oct. 7 -- ClinicalTrials.gov registry received information related to the study (NCT07860216) titled 'Phase III Clinical Trial of Recombinant Respiratory Syncytial Virus Vaccine (CHO Cells)' on Sept. 12.

Brief Summary: This is a phase III clinical trial with a multicenter, randomized, blinded, placebo-controlled design to evaluate the protective efficacy, safety, and immunogenicity of the recombinant respiratory syncytial virus (RSV) vaccine (CHO cell) in individuals aged 60 and above.

Sample Size and Trial Grouping: This trial plans to enroll 25,000 trial participants aged >=60 years (with approximately 30% aged 70 and above), with a relatively balanced gender distribution. Participants of each age group (60-69 years old, >=70 year...